<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02602483</url>
  </required_header>
  <id_info>
    <org_study_id>JAN12006-01</org_study_id>
    <nct_id>NCT02602483</nct_id>
  </id_info>
  <brief_title>Exploratory Study To Assess the Efficacy and Safety of a Triple Combination for Acute Pain Treatment in Patients With Temporomandibular Joint Disorders (TMJD).</brief_title>
  <official_title>Randomized, Double Blind, Placebo Controlled Exploratory Study To Assess the Efficacy and Safety of a Triple Combination of Ibuprofen+Mg+Ascorbic Acid for Acute Pain Treatment in Temporomandibular Join Disorder (TMJD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spherium Biomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitat Internacional de Catalunya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Odontològic UB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Rey Juan Carlos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spherium Biomed</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objetive of this study is to explore the efficacy and safety of a triple combination of
      ibuprofen, magnesium and ascorbic acid for acute pain treatment in TMJD patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain level from baseline compared to placebo assessed by a pain VAS scale</measure>
    <time_frame>seven days</time_frame>
    <description>Pain level is measured according to visual analogue scale (VAS, 0-100 mm) before and 7 days after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline compared to placebo assessed by RDC/TMD questionnaire at day 3 +/-1 and at day 7.</measure>
    <time_frame>seven days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Temporomandibular Joint Disorders</condition>
  <arm_group>
    <arm_group_label>Triple combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Powder for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium + ascorbic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Powder for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Powder for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>Triple combination</arm_group_label>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium</intervention_name>
    <arm_group_label>Triple combination</arm_group_label>
    <arm_group_label>Magnesium + ascorbic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <arm_group_label>Triple combination</arm_group_label>
    <arm_group_label>Magnesium + ascorbic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. TMD dysfunction syndrome patients of RDC/TMD Groups Ia and/or Ib (+/- IIIa and/or
             IIIb); with moderate to severe pain (VAS &gt;4), refractory to conservative treatment
             (including splint / local prosthesis)

          2. Subjects between 18 and 65 years.

          3. Body weight within the normal range (IMC index between 19 and 30) expressed as weight
             (kg) /height (m2).

          4. Physical condition according to ASA I or II (American Society of Anesthesiologists)

          5. Having not participated in previous clinical trial during the three months preceding
             the setting-up of this study.

          6. Free acceptance to collaborate in the study, expressed by signature of written
             informed consent by the participant

        Exclusion Criteria:

          1. Patients who are pregnant or breastfeeding.

          2. Patients who have a consumption of enzyme-inducing drugs within the 30 days prior to
             the study: carbamazepinam, nevirapine, phenobarbital, rifampin, secobarbital and St.
             John's wort.

          3. Patients who are consuming: acetaminophen, acetyl salicylic acid, bemiparina,
             clonixidina, oral anticoagulant, heparin and derivatives, systemic corticosteroids,
             pemetresed, digoxin, phenytoin, lithium, methotrexate, Salicylates, NSAIDs, antacids
             containing aluminum, such as algeldrato, magaldrate, morphine and its derivatives.

             Patients who have been medicated with NSAIDs or Morphic derivatives for the treatment
             of pain of TMD prior to attending the consultation will be included whether, they meet
             a washout period of 8 to 12 hours (depending on the medication taken) before being
             included in the study.

          4. Patients with underlying systemic pathology candidate to receive drug treatment with
             analgesic.

          5. In patients with a history of gastrointestinal bleeding or perforation related to
             previous treatment with NSAIDs. Peptic ulcer / active or recurrent gastrointestinal
             hemorrhage (two or more episodes of ulceration) or proven hemorrhage.

          6. Patients with active Ulcerative colitis or Crohn's disease. Severe heart failure.
             Severe renal dysfunction. Severe hepatic dysfunction.

          7. Patients with urolithiasis by oxalate

          8. History of alcoholism or drug dependence within 3 months prior to the screening visit,
             and / or, History of psychotropic drugs consumption within 3 months prior to the
             screening visit.

          9. Heavy consumer of stimulating beverages (&gt;5 coffees, teas, or cola drinks per day).

         10. History of drug allergy, idiosyncrasy or hypersensitivity. 11 Patients with
             cerebrovascular bleeding or other active bleeding 12 Patients with bleeding diathesis
             or other bleeding disorders .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giner Lluis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universitaria Odontologica de la Universidad Internacional de Cataluña</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universitaria Odontològica de la Universitat Internacional de Catalunya</name>
      <address>
        <city>Sant Cugat del Valles</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Odontològic de la Universitat de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08027</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>temporomandibular</keyword>
  <keyword>joint</keyword>
  <keyword>pain</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>magnesium</keyword>
  <keyword>vitamin C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

